Transcatheter pulmonary valve replacement in surgically‐created double‐barrel right ventricular outflow tracts: A single center case‐series

Abstract

This manuscript describes the feasibility and approach to the assessment and performance of transcatheter pulmonary valve replacement (tPVR) in patients with surgically‐created “double‐barrel” right ventricular outflow tracts (RVOT). Patients with tetralogy of Fallot may have coronary anomalies which prohibit the performance of traditional tetralogy of Fallot repair. In certain cases, this may necessitate the placement of a right ventricle to pulmonary artery conduit in addition to the native RVOT, which is left in situ, creating so‐called “double‐barrel” RVOTs. When these patients develop RVOT dysfunction later in life, they would typically be referred for reoperation due to concerns for risk of coronary compression associated with a transcatheter approach. However, whether a transcatheter approach with valve replacement in the native RVOT is feasible or safe is unknown. This was a retrospective review of patients with a surgically created “double‐barrel” RVOTs who underwent cardiac catheterization for assessment of tPVR at Boston Children's Hospital. From July 2012 to July 2022, there were four patients with “double‐barrel” RVOTs who underwent assessment for tPVR. The age at catheterization ranged between 22 and 39 years. In three out of four patients, coronary compression testing was negative. These three patients had successful tPVR in the native RVOT. At follow up, all three patients were free of greater than mild regurgitation by echocardiogram and had a maximum instantaneous gradient across the RVOT ranging between 20 and 33 mmHg. Performance of tPVR in patients with surgically created “double‐barrel” RVOTs is feasible. The safety of this procedure depends crucially on coronary artery assessment at all stages.

Keywords: CHDA—Congenital heart disease in adults; CONP—Congenital Heart Disease; CORA—Coronary Anomaly; pediatrics; percutaneous intervention; PVD—Pulmonary Valve Disease.